Project: Nanomedicine for glioblastoma therapy
| Acronym | NANO4GLIO (Reference Number: EURONANOMED2019-117) |
| Duration | 01/01/2020 - 31/12/2022 |
| Project Topic | The main objective of this project is to establish a new therapeutic approach for cancer treatment in general and for glioblastoma in particular, a tumor for which there is no effective treatment. The novelty of the project relies not only on the use of RNAi technology (more specifically siRNA) to knock down selected proteins involved in tumoral cell survival and proliferation making them more susceptible to anticancer drugs and/or radiation but also in the use of novel cutting-edge multitasking nanoparticles (NPs). The specific siRNAs will be target-delivered by these NPs that will be fine-tuned in their structure and chemical surface to perform efficiently the tasks required for targeting an intracerebral glioblastoma xenograft: blood-brain barrier crossing, siRNA target-delivered or tumor imaging. There are several relevant issues that are addressed by the project: a) Improving BBB crossing by NPs; b) toxicity of the NPs in vivo and in vitro (on healthy and tumoral cells); c) fine-tuning of the 3D structure of the NPs based on feedback from biological experiments and d) the use of selected fresh xenografted human tumors obtained from cells isolated from patients to increase the likeliness that the response of the mice to the nanoplexes could enhance our understanding of key aspects of glioblastoma biology and, in proper time, reach the clinical setting. The project will use a multidisciplinary approach strategy and all the techniques that are going to be used in the project are commonly used in the laboratories of the members of the consortium which decreases the technological risk of the project. The final result of the development of the project will be to provide the “proof-of-concept” in an animal model of xenografted human glioblastoma cells, obtained from patients by the clinicians participating in the consortium, that RNAi therapeutics is effective in cancer treatment either by itself or by potentiating the effect of anticancer drugs. |
| Network | EuroNanoMed III |
| Call | Joint Transnational Call (2019) |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Universidad de Castilla-La Mancha | Coordinator | Spain |
| 2 | CNRS | Partner | France |
| 3 | Institut National de Recherche Scientifique (INRS)-IAF | Partner | Canada |
| 4 | Kaohsiung Medical University | Partner | Taiwan |
| 5 | Glycovax | Partner | Canada |
| 6 | Ramon y Cajal University Hospital | Partner | Spain |
| 7 | State Education Development Agency/Valsts izglitibas attistibas agentura (SEDA/VIAA) | Partner | Latvia |